Atopic disease, rhinitis and conjunctivitis, and upper respiratory infections

Current Opinion in Pediatrics

Volumn 9, Issue 5, 1997, Pages 537-547

  Schneider, Lynda C ^a   Lester, Mitchell R ^a  

^a BOSTON CHILDREN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LEUKOTRIENE;

ANAPHYLAXIS; ARTICLE; ATOPIC DERMATITIS; ATOPY; CONJUNCTIVITIS; EGG; EXERCISE; FOOD ALLERGY; HUMAN; PEANUT; PRIORITY JOURNAL; RHINITIS; RHINOCONJUNCTIVITIS; UPPER RESPIRATORY TRACT INFECTION;

EID: 0030664992     PISSN: 10408703     EISSN: None     Source Type: Journal    
DOI: 10.1097/00008480-199710000-00018     Document Type: Article

References (92)

1. Lapidus C, Schwarz D, Honig P: Atopic dermatitis in children: Who cares? Who pays? J Am Acad Dermatol 1993, 28:699-703.
2. Su J, Kemp A, Varigos G, Nolan T: Atopic eczema: its impact on the family and financial cost Arch Dis Child 1997, 76:159-162. This study looked at the impact of atopic dermatitis on families, and assessed the financial cost of caring for 48 children with mild, moderate, and severe atopic dermatitis in comparison with a group of 46 children with diabetes. The results highlight the tremendous impact of atopic dermatitis on families.
3. Herd R, Tidman M, Prescott R, Hunter J: The cost of atopic eczema. Br J Dermatol 1996, 135:20-23.
4. Williams H, Bumey P, Pembroke A, Hay R: The U.K. Working Party's Diagnostic Criteria for Atopic Dermatitis: III. Independent hospital validation. Br J Dermatol 1994, 131:406-416.
5. Williams H, Burney P, Pembroke A, Hay R: Validation of the U.K. diagnostic criteria for atopic dermatitis in a population setting. Br J Dermatol 1996, 135:12-17.
6. Yamashita N, Kaneko S, Kouro O, Furue M, Yamamoto S, Sakane T: Soluble E-selectin as a marker of disease activity in atopic dermatitis. J Allergy Clin Immunol 1997, 99:410-416.
7. Berth-Jones J, Finlay AY, Zaki I, Tan B, Goodyear H, Lewis-Jones S, Cork MJ, Bleehan SS, Salek S, Allen BR, et al.: Cyclosporine in severe childhood atopic dermatitis: a multicenter study. J Am Acad Dermatol 1996, 34:1016-1021.
8. 1-antitrypsin decreased.
9. Majamaa H, Isolauri E: Evaluation of the gut mucosal barrier evidence for Increased antigen transfer in children with atopci eczema. J Allergy Clin Immunol 1996, 97:985-990.
10. Fischer G: Compliance problems in paediatric atopic eczema. Australasian J Dermatol 1996, 37:S10-S13. This article presents the results of a survey of parents of children with atopic dermatitis who were seen by dermatologists. Major reasons for failure to comply with the therapy included a poor understanding of the chronic nature of the disease, a fear of topical steroids, and the time and cost of treatment. Suggested methods to handle these concerns are discussed.
11. Werfel S, Cooke S, Sampson H: Clinical reactivity to beef in children allergic to cow's milk. J Allergy Clin Immunol 1997, 69:293-300.
12. American Academy of Pediatrics: Active and passive Immunization. In 1997 Red Book: Report of the Committee on Infectious Diseases, edn 24. Edited by Peter G. Elk Grove Village, IL: American Academy of Pediatrics; 1997:32-34. Outlines the new recommendations that MMR testing is not required in egg-allergic children.
13. James J, Burks A, Roberson P, Sampson H: Safe administration of the measles vaccine to children allergic to eggs. N Engl J Med 1995, 332:1262-1266.
14. Kelso J, Jones R, Yunginger J: Anaphylaxls to measles, mumps, and rubella vaccine mediated by IgE to gelatin. J Allergy din Immunol 1993, 91:867-872.
15. Masahiro S, Nakayama T, Inouye S: Food allergy to gelatin in children with systemic Immediate-type reactions, Including anaphylaxis, to vaccines. J Allergy Clin Immunol 1996, 98:1058-1061. Twenty-six children who had systemic allergic reactions to MMR vaccines were evaluated for specific IgE to gelatin. Twenty-four of 26 had antigelatin IgE
16. Masahiro S, Yamanaka T, Ikeda K, Sano Y, Fujita H, Miura T, Inouye S: IgE-mediated systemic reactions to gelatin included in the varicella vaccine. J Allergy Clin Immunol 1997, 99:263-264.
17. Nickel R, Kulig M, Forster J, Bergmann R, Bauer CP, Lau S, GuggenmoosHolzmann I, Wahn U: Sensltizatlon of hen's egg at the age of twelve months is predictive for allergic sensitlzation to common indoor and outdoor allergens at the age of three years. J Allergy Clin Immunol 1997, 99:613-617.
18. Sasai K, Furukawa S, Muto T, Baba M, Yabuta K, Fukuwatari Y: Early detection of specific IgE antibody against house dust mite in children at risk of allergic disease. J Pediatr 1996, 128:834-840. To predict who will develop dust mite sensitivity, the authors evaluated a group of 108 infants with recurrent wheezing or pruritic dermatitis. At 5 years of age, 54 of 108 patients had positive house dust mite IgE. In a multiple regression analysis, a high serum IgE level, a positive reaction to specific IgE antibody against egg white, and a house dust mite IgE level of between 0.23 and 0.35 (< 0.35 is considered negative) at 6 months of age were significant future predictors of dust mite sensitivity at age 5 years. Determination of these predictors in 6-month-old infants may be helpful to predict future allergic disease. Counseling of families in environmental control measures may be helpful to prevent or modify allergic disease.
19. Tariq S, Stevens M, Matthews S, Ridout S, Twiselton R, Hide D: Cohort study of peanut and tree nut sensitizatlon by age of 4 years. BMJ 1996, 313:514-517. This is one of the first studies to look at the prevalence of peanut and nut allergy. This birth cohort study looked at the prevalence on the Isle of Wight of sensitization to peanuts and tree nuts at 1,2, and 4 years of age. Fifteen of 1218 children were sensitive to peanut or tree nuts (1.2%). Eight of the 15 patients had allergic reactions to peanuts or tree nuts and seven patients were identified as sensitized on the basis of skin testing alone. Family history of atopy, allergy to egg, and eczema were important predictors of peanut allergy.
20. O'B Hounhane J, Dean T, Warner J: Peanut allergy in relation to heredity, maternal diet, and other atopic diseases: results of a questionnaire survey, skin prick testing, and food challenges. BMJ 1996, 313:518-521.
21. Ewan P: Clinical study of peanut and nut allergy in 62 consecutive patients: new features and associations. BMJ 1996, 312:1074-1078. This study looked at the clinical characteristics of 62 peanut and tree nut allergic patients. One third of patients allergic to peanuts also developed allergy to one or more tree nuts. The most common symptom of an allergic reaction was facial angioedema. The most serious feature was laryngeal edema, which occurred in 27 of 62 patients. Hypotension occurred in seven patients. Children with peanut allergy were found to be at an increased risk of developing allergy to tree nuts.
22. Teuber S, Brown R, Haapanen L: Allergenicity of gourmet nut oils processed by different methods. J Allergy Clin Immunol 1997, 99:502-507.
23. O'B Hourihane J, Bedwani S, Dean T, Warner J: Randomized, double blind, crossover challenge study of allergentcity of peanut oils in subjects allergic to peanuts. BMJ 1997, 314:1084-1088.
24. Tilles S, Schocket A, Milgrom H: Exercise-induced anaphylaxis related to specific foods. J Pediatr 1995, 127:587-589.
25. Caffarelli C, Terzi V, Perrone F, Cavagni G: Food related, exercise Induced anaphylaxis. Arch Dis Child 1996, 75:141-144.
26. Kemp S, Lockey R: Peanut anaphylaxis from food cross-contamination. JAMA 1996, 275:1636-1637.
27. Steinman H: "Hidden" allergens in foods. J Allergy Clin Immunol 1996, 98:241-250. Comprehensive review of food allergens and where they may exist in common foods. The article reviews specific details on egg, milk, soy, wheat, peanuts, and fish. Several tables list product label terminology for the food allergen and foods that may contain the food allergen.
28. Blanco C, Quiralte J, Castillo R, et al.: Anaphylaxis after ingestion of wheat flour contaminated with mites. J Allergy Clin Immunol 1997, 99:308-313.
29. Terr A, Bloch D: Trends in asthma therapy in the United States: 1965-1992. Ann Allergy Asthma Immunol 1996, 76:273-281. Prescriptions for inhaled corticosteroids in the United States increased dramatically between 1989 and 1992. Inhaled β-agonist use increased between 1978 and 1992. The first consensus guidelines for asthma management (National Heart, Lung, and Blood Institute; Guidelines for the Diagnosis and Management of Asthma. Bethesda: National Institutes of Health; 1991) were published in 1991, and data as to whether prescribing trends have continued are not yet published. A continued increase in the use of inhaled anti-inflammatory medications coupled with a decrease in the use of inhaled bronchodilators would be satisfying.
30. National Heart, Lung, and Blood Institute: Guidelines for the Diagnosis and Management of Asthma. Bethesda: National Institutes of Health; 1991.
31. Donahue J, Weiss S, Livingston J, Goetsch M, Greineder D, Platt R: Inhaled steroids and the risk of hospitalization for asthma. JAMA 1997, 277:887-891. This study is an important addition to the multiple studies demonstrating improved pulmonary function and symptom control with inhaled anti-inflammatory medications. The authors show that inhaled corticosteroid use and, to a lesser extent, cromolyn sodium use decreased the relative risk of hospitalization for asthma. The protective effect was greatest among those with the greatest use of β-agonist rescue medications.
32. National Heart, Lung, and Blood Institute: Expert Panel Report II: Guidelines for the Diagnosis and Management of Asthma. Bethesda: National Institutes of Health; 1997. These revised guidelines are intended for primary care physicians. Management algorithms and their rationale are discussed and referenced. In addition, new medications and controversies in asthma management are addressed. This important document is available from the National, Heart, Lung, and Blood Institute for a nominal fee.
33. Cockcroft D, Swystun V: Asthma control versus asthma severity. J Allergy Clin Immunol 1996, 98:1016-1018. The authors' discussion of asthma severity in well-controlled asthma serves an important reminder that asthma is a chronic, not an episodic, disease. As a result, it is not always possible to "step-down" therapy, let alone "step-off" therapy.
34. Laitinen L, Laitinen A: Remodeling of asthmatic airways by glucocorticosteroids. J Allergy Clin Immunol 1996, 97:153-158.
35. Laitinen L, Laitinen A, Altraja A, Virtanen I, Kampe M, Simonsson B, Karisson S, Hakansson L, Venge P, Sillastu H: Bronchial biopsy findings in intermittent or "early" asthma. J Allergy Clin Immunol 1996, 98:S3-S6.
36. Burke C, Sreeman S, Pathmakanthan S, Patlerson J, Schmeckel B, Poulter L: Relative effects of inhaled corticosteroids on immunopathology and physiology in asthma: a controlled study. Thorax 1996, 51:993-999.
37. Cho S, Seo J, Choi D, Yoon H, Cho Y, Min K, Lee G, Seo J, Kim Y: Pathological changes according to the severity of asthma. Clin Exp Allergy 1996, 26:1210-1216. Few studies have correlated asthma severity with pathology. Even patients with mild asthma have airway inflammation and early stages of airway remodeling. This retrospective outcome study also demonstrates that regular use of inhaled anti-inflammatory medications improves pulmonary function and decreases asthma symptoms. At the same time, they decrease the need for emergency department visits and hospitalisations for asthma. Any physician treating patients whose conditions are not responding to therapy should read this paper. Patients who volunteered for a study had only 58.4% compliance with inhaled medications as measured with a chronolog, but reported 95.4% compliance. Compliance was lowest in patients with asthma exacerbations. Medication compliance is an important issue to address in patients with poorly controlled asthma.
38. Konig P, Shatter J: The effect of drug therapy on long-term outcome of childhood asthma: a possible preview of the International guidelines. J Allergy Clin Immunol 1996, 98:1103-1111. This retrospective outcome study also demonstrates that regular use of inhaled anti-inflammatory medications improves pulmonary function and decreases asthma symptoms. In addition, they decrease the need for emergency department visits and hospitalisations for asthma.
39. Overbeek S, Kerstjens H, Bogaard J, Mulder P, Postrna D, Dutch Chronic Nonspecific Lung Disease Study Group: Is delayed Introduction of inhaled corttcosteroids harmful in patients with obstructive airways disease (asthma and COPD)? Chest 1996, 110:35-41.
40. Milgrom H, Bender B, Ackerson L, Bowry P, Smith B, Rand C: Noncompliance and treatment failure in children with asthma. J Allergy Clin Immunol 1996, 98:1051-1057. Any physician treating patients whose conditions are not responding to therapy should read this paper. Volunteer patients had only 58.4% compliance with inhaled medications as measured with a chronolog, but reported 95.4% compliance. Compliance was lowest in patients with asthma exacerbations. Medication compliance is an important issue to address in patients with poorly controlled asthma.
41. Schneider L, Lester M: Atopic disease, rhinitis and conjunctivitis, and upper respiratory Infections. Curr Opin Pediatr 1996, 8:531-540.
42. Smith L: Leukotrienes in asthma: the potential role of antileukotriene agents. Arch Intern Med 1996, 156:2181-2189.
43. Busse W: The role of leukotrienes in asthma and allergic rhinitis. Clin Exp Allergy 1996, 26:868-879.
44. Holgate S, Bradding P, Sampson A: Leukotrlene antagonists and synthesis Inhibitors: new directions in asthma therapy. J Allergy Clin Immunol 1996, 98:1-13. An excellent concise review of the role of leukotrienes in asthma, the effects of antileukotriene medications, and their role in asthma therapy.
45. Turner C, Breslow R, Conklyn M, Andresen C, Patterson D, Lopez-Anaya A, Owens B, Lee P, Watson J, Showell H: In vitro and in vivo effects of leukotriene B4 antagonism in a primate model of asthma. J Clin Invest 1996, 97:381-387.
46. Spector S: Management of asthma with zafirlukast. Drugs 1996, 52(suppl 6):36-46.
47. McGill K, Busse W: Zileuton. Lancet 1996, 348:519-524.
48. Suissa S, Dennis R, Ernst P, Sheehy O, Wood-Dauphinee S: Effectiveness of the leukotriene antagonist zaflrlukast for mild-tomoderate asthma. Ann Intern Med 1997, 126:177-183. In a double-blind, placebo-controlled study, 103 patients with mild-to-moderate asthma received zafirlukast for 13 weeks. Compared with placebo-treated subjects, the study group had significantly better controlled asthma despite less use of rescue β-agonists. The zafirlukast-treated subjects required fewer doctor visits and had better attendance at school and work than the placebo-treated control subjects. The cost of the medication was not assessed, so monetary savings in direct and indirect costs of asthma cannot be calculated from this study.
49. Reiss T, Altman L, Chervinsky P, Bewtra A, Stricker W, Noonan G, Kundu S, Zhang J: Effects of montelukast (MK-0476), a new potent cysteinyl leukotriene (LTD4) receptor antagonist in patients with chronic asthma. J Allergy Clin Immunol 1996, 98:528-534.
50. Tamaoki J, Kondo M, Sakai N, et al: Leukotriene antagonist prevents exacerbation of asthma during reduction of high-dose inhaled cortlcosteroid. Am J Respir Crit Care Wed 1997, 155:1235-1240. Forty-seven patients requiring high-dose inhaled corticosteroids were treated with zafirlukast. Compared with placebo-treated control patients, the zafirlukasttreated patients were able to maintain control of their asthma with a 50% inhaled steroid dose reduction, placing them at a lesser risk of systemic side effects from their inhaled medication.
51. Meltzer S, Hasday J, Cohn J, Bleecker E: Inhibition of exercise-induced bronchospasm by zileuton: a 5-lipoxygenase inhibitor. Am J Respir Crit Care Med 1996, 153:931-935.
52. Israel E, Cohn J, Dube L, Drazen J: Effect of treatment with zileuton. a 5- lipoxygenase inhibitor, in patients with asthma. JAMA 1996, 275:931-936. This 3-month study proves the effectiveness of zileuton in the treatment of mild-to-moderate persistent asthma. Compared with patients treated only with β-agonists, subjects who received zileuton 600 mg twice daily had significantly better asthma control and improved quality of life. The study also demonstrates the importance of monitoring liver function in treated patients.
53. Liu M, Dube L, Lancaster J, Zileuton Study Group: Acute and chronic effects of a 5-lipoxygenase Inhibitor in asthma: a 6-month randomized multicenter trial. J Allergy Clin Immunol 1996, 98:859-871.
54. Ind P: Anti-leukotriene Intervention: is there adequate Information for clinical use in asthma? Respir Med 1996, 90:575-586.
55. Nimmagadda S, Spahn J, Leung D, Szefler S: Steroid-resistant asthma: evaluation and management Ann Allergy Asthma Immunol 1996, 77:345-356.
56. Nimmagadda S, Szefler S, Spahn J, Surs W, Leung D: Allergen exposure decreases glucocorttcold receptor binding affinity and steroid responsiveness in atopic asthmatics. Am J Respir Crit Care Med 1997, 155:87-93.
57. Lock S, Kay A, Barnes N: Double-blind, placebo-controlled study of cyclosporin A as a corticosteroid-sparing agent in corticosteroiddependent asthma. Am J Respir Crit Care Med 1996, 153:509-514.
58. Sole D, Costa-Carvalho B, Scares F, Rullo V, Naspitz C: Methotrexate in the treatment of corttcosterold dependent asthmatic children. J Invest Allergy Clin Immunol 1996, 6:126-130.
59. Gelfand E, Landwehr L, Esterl B, Mazer B: Intravenous Immunoglobulin: an alternative therapy in steroid dependent allergic diseases. Clin Exp Immunol 1996, 104(suppl 1):61-66.
60. Bernstein I, Bernstein D, Dubb J, Faiferman I, Wallin B: A placebocontrolled mutttcenter study of auranofln in the treatment of patients with corticosteroid-dependent asthma: auranofin multicenter drug trial. J Allergy Clin Immunol 1996, 98:317-324.
61. Gershwin M, Terr A (eds.): Alternative and complementary therapy for asthma. Clin Rev Allergy Immunol 1996, 14:241-355.
62. Gore W, Tansey I (Chairs): Ensuring Patient Care: The Role of the MFC MDI. Washington, DC: International Pharmaceutical Aerosol Consortium; 1997. This report was prepared to inform the United Nations Environment Program about the transition from chlorofluorocarbon-propelled MDIs and the role of hydrofluoroalkane-propelled MDIs in the treatment of respiratory disease. This report is available directly from the consortium.
63. Dockhom R, Vanden Burgt J, Ekholm B, Donnell D, Cullen M: Clinical equivalence of a novel non-chlorofluorocarbon-containing salbutamol sulfate metered-dose Inhaler and a conventional chlorofluorocarbon Inhaler in patients with asthma. J Allergy Clin Immunol 1995, 96:50-56.
64. Kleerup E, Tashkin D, Cline A, Ekholm B: Cumulative dose-response study of non-CFC propellant HFA 134a salbutamol sulfate metereddose inhaler in patients with asthma. Chest 1996, 109:702-707.
65. Chapman K, Friberg K, Baiter M, Hyland R, Alexander M, Abboud R, Peters S, Jennings B: Albuterol via Turbuhaler versus albuterol via pressurized metered-dose Inhaler in asthma. Ann Allergy Asthma Immunol 1997, 78:59-63.
66. Gioulekas D, Papakosta D, Vordoyianni P, Baloti H, Vamvalis C: A comparison of the clinical efficacy and patient acceptability of terbutaline Turbuhaler and salbutamol Rotahalar in adult patients with asthma. Respir Med 1996, 90:205-209.
67. Pauwels R, Hargreave F, Camus P, Bukoski M, Stahl E: A 1-year compar- ison of Turbuhaler vs. pressurized metered-dose inhaler in asthmatic patients. Chest 1996, 110:53-57. This open-label comparison of Turbuhaler to pressurized MDI demonstrates the ease with which patients may be changed from one delivery system to another.
68. Toogood J, White F, Baskerville J, Fraher L, Jennings B: Comparison of the antiasthmatlc, oropharyngeal, and systemic glucocortlcold effects of budesonlde administered through a pressurized aerosol plus spacer or the Turbuhaler dry powder inhaler. J Allergy Clin Immunol 1997, 99:186-193.
69. Meijer R, van der Mark T, Aalders B, Postma D, Koeter G: Home assessment of peak Insplratory flow through the Turbuhaler in asthmatic patients. Thorax 1996, 51:433-434.
70. Hannaway P: Failure of a breath-actuated bronchodilator Inhaler to deliver aerosol during a bout of near fatal asthma (letter). J Allergy Clin Immunol 1996, 98:853. This letter indicates a risk of reliance on a breath-actuated inhalation device during severe asthma exacerbations.
71. de Blic J, Delacourt C, Le Bourgeois M, Mahmut B, Ostinelli J, Coswell C, Scheinmann P: Efficacy of nebulized budesonlde in treatment of severe infantile asthma: a double blind study. J Allergy Clin Immunol 1996, 98:14-20.
72. Leflein J, Brown E, Hill M, Kelly H, Loffert D, Nelson H, Szefler S: Delivery of glucocorticolds by jet nebulizatlon: aerosol characteristics and output J Allergy Clin Immunol 1995, 95:944-949.
73. Malone D, Lawson K, Smith D, Arrighi H, Battista C: A cost of illness study of allergic rhinitis in the United States. J Allergy Clin Immunol 1997, 99:22-27.
74. Juniper J: Measuring health-related quality of life in rhinitis. J Allergy Clin Immunol 1997, 99:3742-8749. Ultimately, many patients measure the success of prescribed treatment by how it improves their quality of life. Although allergic rhinitis is often considered a trivial disease, its impact on the day-to-day activities of those affected can be great, thus justifying aggressive therapy for symptom control. Juniper's work has been focal to our understanding of how to measure health-related quality of life.
75. Bousquet J, Duchateau J, Pignant C, Fayol C, Marquis P, Mariz S, Ware J, Valentin B, Burtin B: Improvement of quality of life by treatment with cetirizine in patients with perennial allergic rhlnitis as determined by a French version of the SF-36 questionnaire. J Allergy Clin Immunol 1996, 98:309-316.
76. Baraniuk J: Pathogenesis of allergic rhinitis. J Allergy Clin Immunol 1997, 99:8763-8772.
77. Spector S: Overview of comorbid associations of allergic rhinitis. J Allergy Clin Immunol 1997, 99:8773-8780.
78. Du Buske L: Clinical comparison of histamlne HI-receptor antagonists drugs. J Allergy Clin Immunol 1996, 98:S307-S318.
79. Woosley R: Cardiac actions of antlhlstamines. Ann Rev Pharmacol Toxicol 1996, 36:233-252.
80. FDA proposes to withdraw Seldane approval. FDA Med Bull 1997, 27.
81. LaForce C, Dockhom R, Prenner B, Chu T, Kraemer M, Widlitz M, D'Eletto T, Freitag J: Safety and efficacy of azelastlne nasal spray (Astelln NS) for seasonal allergic rhinitis: a 4-wsek comparative multicenter trial. Ann Allergy Asthma Immunol 1996, 76:181-188. Azelastine, a new class of topical antiallergic medication, is as effective as chlorpheniramine in reducing symptoms of allergic rhinitis when used as two sprays per nostril twice daily.
82. Azelastine nasal spray for allergic rhinitis. Med Lett Drugs Ther 1997, 39:45-47.
83. Foresi A, Pelucchi A, Gherson G, Mastropasqua B, Chiappanno A, Testi R: Once daily intranasal fluticasone propionate (200 micrograms) reduces nasal symptoms and Inflammation but also attenuates the Increase in bronchial responsiveness during the pollen season in allergic rhinitis. J Allergy Clin Immunol 1996, 98:274-282.
84. Jordana G, Dolovich J, Briscoe M, Day J, Drovin M, Gold M, Robson R, Stepher N, Young W: Intranasal fluticasone propionate versus lorata- dine in the treatment of seasonal allergic rhinitis. J Allergy Clin Immunol 1996, 97:533-595. Two hundred-forty adolescents with seasonal allergic rhinitis to ragweed were treated with daily intranasal fluticasone as an anti-inflammatory medication or oral loratidine for regular relief of symptoms. The former group had significantly more symptom-free days, fewer symptoms of allergic rhinitis, tess nasal blockage, and improved nasal air flow. As has been demonstrated in asthma, patients with frequent severe symptoms derive greater benefit from regular preventive medication than from symptom relievers alone.
85. Richards D, Milton C: Fluticasone propionate aqueous nasal spray: a welt-tolerated and effective treatment for children with perennial rhinitis. Pediatr Allergy Immunol 1996, 7:35-43.
86. Andersen D: The conjunctival late-phase reaction and allergen provocation in the eye (editorial). Clin Exp Allergy 1996, 26:1105-1107.
87. Montan P, van Hage-Hamsten M, Zetterstrom O: Sustained eosinophil cationic protein release into tears after a single high-dose conjunctival allergen challenge. Clin Exp Allergy 1996, 26:1125-1130.
88. Sharif N, Xu S, Miller S, Gamache D, Yanni J: Characterization of the ocular antiallergic and antihistaminic effects of olopatadine (AL-4943A), a novel drug for treating ocular allergic diseases. J Pharmacol Exp Ther 1996, 278:1252-1261.
89. Turner R: Epidemiology, pathogenesis, and treatment of the common cold. Ann Allergy Asthma Immunol 1997, 78:531-540. An excellent review article on the common cold. The rationale for therapy is discussed in the context of the pathogenesis. The treatment section outlines specific therapies for common symptoms including rhinorrhea, nasal congestion, sore throat, and cough. Prevention is also discussed.
90. Einarsson O, Geba G, Zhu Z, Landry M, Elias J: lnterieukln-11: stimulation in vivo and In vitro by respiratory viruses and Induction of airways hyperresponsiveness. J Clin Invest 1996, 97:915-924.
91. Mossad S, Macknin M, Medendorp S, Mason P: Zinc gluconate lozenges for treating the common cold: a randomized, double-blind, placebo controlled study. Ann Intern Med 1996, 125:81-88.
92. Cohen S, Doyle W, Skoner D, Rabin B, Gwaltney J Jr: Social ties and susceptibility to the common cold. JAMA 1997, 277:1940-1944. Although this study included adults, it is included in this review because URIs are so important in pediatrics. When 276 healthy adults were given nasal drops with rhinovirus, the participants with six or more types of social relationships were less susceptible to commons colds, produced less mucus, were more effective in clearance of the nasal passages, and shed less virus. Although smoking, poor sleep quality, alcohol abstinence, low dietary intake of vitamin C, elevated catecholamine levels, and being introverted were all associated with greater susceptibility to colds, they could only partially explain the relation between social diversity network and the incidence of colds.